Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The Primary efficacy objective is to compare Recurrence Free Survival (RFS) in the patients treated with sorafenib vs placebo after receiving potentially curative treatment with surgical resection or local ablation.
Inclusion criteria
- To evaluate clinical benefits of sorafenib vs placebo as adujuvant treatment in subjects with HCC who received potentially curative treatment (surgical resection or local ablation)